Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiyao Liu

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
The Lancet. Child & Adolescent Health|October 16, 2025
Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysisAnna de Geus, Morris Gordon, Vassiliki Sinopoulou, et al.
Materials Today. Bio|April 1, 2025
Bioinspired hydrogel for sustained minocycline release: A superior periodontitis solutionShiyao Liu, Wenqian Zheng, Lina Wang, et al.
Plant Physiology|August 30, 2023
Arabidopsis membrane protein AMAR1 interaction with type III effector XopAM triggers a hypersensitive responseQingbiao Xie, Bingzheng Wei, Zhaohong Zhan, et al.
British Journal of Clinical Pharmacology|June 22, 2018
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumabCornelius F Waller, Apinya Vutikullird, Tracey E Lawrence, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 12, 2025
Halofuginone targets Serine/Glycine synthesis to reverse epidermal growth factor receptor Tyrosine Kinase inhibitor resistance in lung adenocarcinomaYongping Li, Peipei Liu, Shiyao Liu, et al.
Advances in Therapy|June 10, 2025
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for InterchangeabilitySarika Deodhar, Subramanian Loganathan, Ramesh Kadadanamari Subbarama Reddy, et al.
Journal of Cancer Research and Clinical Oncology|April 20, 2018
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastimCornelius F Waller, Renger G Tiessen, Tracey E Lawrence, et al.
Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
The Lancet. Child & Adolescent Health|October 16, 2025
Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysisAnna de Geus, Morris Gordon, Vassiliki Sinopoulou, et al.
Materials Today. Bio|April 1, 2025
Bioinspired hydrogel for sustained minocycline release: A superior periodontitis solutionShiyao Liu, Wenqian Zheng, Lina Wang, et al.
Plant Physiology|August 30, 2023
Arabidopsis membrane protein AMAR1 interaction with type III effector XopAM triggers a hypersensitive responseQingbiao Xie, Bingzheng Wei, Zhaohong Zhan, et al.
British Journal of Clinical Pharmacology|June 22, 2018
A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumabCornelius F Waller, Apinya Vutikullird, Tracey E Lawrence, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 12, 2025
Halofuginone targets Serine/Glycine synthesis to reverse epidermal growth factor receptor Tyrosine Kinase inhibitor resistance in lung adenocarcinomaYongping Li, Peipei Liu, Shiyao Liu, et al.
Advances in Therapy|June 10, 2025
Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for InterchangeabilitySarika Deodhar, Subramanian Loganathan, Ramesh Kadadanamari Subbarama Reddy, et al.
Journal of Cancer Research and Clinical Oncology|April 20, 2018
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastimCornelius F Waller, Renger G Tiessen, Tracey E Lawrence, et al.
Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<i>ALK</i>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Melanoma Research|October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600ESigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Pageof 8